Phase 3 clinical trial data for MicroStat, a fixed-combination micro-formulation for pharmacologic mydriasis, showed a statistically and clinically superior mydriatic effect compared with the individual components of the formulation, according to a press release from Eyenovia.
The MIST-1 double-masked, randomized, superiority trial included 64 subjects in whom both eyes were treated on separate days with MicroStat, a fixed combination of phenylephrine 2.5% and tropicamide 1%. Results were compared against subjects treated with tropicamide only or phenylephrine only. The company’s OpteJet
Uncategorized